Joaquín Martínez‐López

Teclistamab in Relapsed or Refractory Multiple Myeloma

Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk et al. · New England Journal of Medicine · 2022 · 990 citations · Full text

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Jesús F. San Miguel, Katja Weisel, Philippe Moreau et al. · The Lancet Oncology · 2013 · 794 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

Juan Flores‐Montero, Luzalba Sanoja-Flores, Bruno Paiva et al. · Leukemia · 2017 · 626 citations · Full text

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

Jesús F. San Miguel, Binod Dhakal, Kwee Yong et al. · New England Journal of Medicine · 2023 · 615 citations · Full text

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Johan Richter, Joëlle Guilhot, Franz Gruber et al. · The Lancet Oncology · 2018 · 587 citations · Full text

Hematological Malignancy, Medicine, Chronic Myeloid Leukaemia +10